Programme

Time

10.00-10.30

10.30-10.35

 

10.35-11.25

 

 

 

 

11.25-11.55

11.55-12.10

12.15-13.50

13.00-13.45

 

 

 

13.50-15.05

 

 

 

 

 

15.05-15.15

15.15-15.40

 

15.40-16.55

 

 

 

 

 

16.55-17.05

17.05-17.50

 

 

17.50-17.55

18.00-19.15

 

Coffee and registration Arg2 image

 

Welcome: Katrin Rittinger, Group Leader, Molecular Structure of Cell Signalling Laboratory, Francis Crick Institute and Mark Carr, Professor of Biochemistry, University of Leicester

Session 1: Small molecule drug discovery case studies, Chaired by Mark Carr

10.35-11.00 - Peter Cherepanov, Group Leader, Chromatin Structure and Mobile DNA Laboratory, Crick Institute, "Mode of action of HIV-1 integrase inhibitros and the mechanism of viral escape"

11.00-11.25 - Nuska Tschammer, Subject Matter Expert, WuXi/Crelux, "Structural Biology in Cancer: Enabling the discovery of novel cancer drugs at atomic precision"

 

Short talks from selected posters introduced by Katrin Rittinger

Sponsors: Mitegen, Wuxi Apptec and Forumatrix

 

Lunch and posters

Parallel round table discussions: (1) How do synchrotron high-throughput pipelines support fragment-based drug discovery? Panel Chair: Rob van Montfort; Panel members: Frank von Delft (Diamond Light Source) and Jose Marquez (EMBL Grenoble)

(2)How can cryo-EM complement a drug discovery pipeline? Panel Chair: Doryen Bubeck (ICL/Crick) Panel members: Daniel Clare (Diamond Light Source), TJ Ragan (University of Leicester) and Jason Van Rooyen (Diamond Light Source)

Session 2: Biologics

13.50-14.15 - Alastair Lawson, Senior Fellow UCB "Ab-enabled small molecule drug discovery"

14.15-14.40 - Svend Kjaer, Structural Biology, Science Technology Platform Deputy, Crick Institute, "Structure-guided design of a bi-paratopic DARPin RET antagonist"

14.40-15.05 - David Matthews, Associate Director, Biotherapeutics, LifeArc, "The impact of structural biology on therapeutic antibody design at LifeArc: anti-PD1 and other tales"

Sponsors: Nanotemper and Peak Proteins

 

Tea break

 

Session 3: Emerging Technologies, Chaired by Richard Bayliss, University of Leeds

15.40 - 16.05 - Aude Echalier-Glazer, Scientific Coordinator, Exscientia, "Accelerating the drug discovery process with artificial intelligence"

16.05-16:30 - Jose Marquez, Head of the Crystallization Facility, EMBL Grenoble, "CrystalDirect: Automated, Remote Controlled Protein to Structure Pipelines for Drug Design"

16.30-16.55 - Martin NobleProfessor of Biomolecular Structure & Anticancer Drug Design, "Rule of 1, fragment screening to assess target ligandability"

 

Sponsors: Integra and Swissci

Keynote Lecture: Stefan Knapp, Institute of Pharmaceutical Chemistry, SGC Node at the Goethe University,  “Rational development of highly selective chemical probes as tools for target validation”

Closing remarks, Professor Mark Carr, Chair of the CRUK Accelerating Cancer Drug Discovery Through Structural Biology Network

Networking reception, to include a tour of the building (must be booked in advance) and an opportunity to view the posters; award of poster prizes, approx 18.00

Networking reception, to include a tour of the building (must be booked in advance), award of poster prizes approximately 18:00.

 

Novel coronavirus (2019-nCoV) and visitor access

At the Crick we are carefully monitoring the spread of novel coronavirus (2019-nCoV), and are putting measures in place to minimise the risk to anyone who is working at the Crick or visiting us.

Please read the information on our website which aligns with advice from Public Health England.

https://www.crick.ac.uk/about-us/visit-us

If you are feeling well and haven’t visited the places listed then we very much look forward to seeing you on the 16 March for a busy day of drug discovery research.

Share this page: